Wyeth

Anna Berkenblit

Jay Marshall Feingold

Daniel Stephen Johnston

Charles Zacharchuk

Gary Dukart

Florence Marie Helene Binlich

Paul Goss

James Joseph Gibbons, Jr

Christina Marie Coughlin

Andrew Louis Strahs

Charles Michael Zacharchuk

Florence Binlich

An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.

Treatment regimen utilizing neratinib for breast cancer

This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.

Anti-tumor activity of CCI-779 in papillary renal cell cancer

A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.

Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Growing community of inventors

Needham, MA, United States of America

Anna Berkenblit